ERBB2 and breast cancer: As a consequence, current methods for BC subtype identification are based on the immunohistochemical expression of oestrogen receptor (ER), progesterone receptor (PR), and Ki-67, along with the expression and/or amplification of the gene encoding the human epidermal growth factor 2 receptor (HER2) [3].